NewCardio (NWCI) Stock Price, News & Analysis

Company Overview

NewCardio, Inc. is a preclinical cardiac safety services company focused on assessing the potential cardiotoxic effects of drug candidates. The firm leverages human induced pluripotent stem cell–derived cardiomyocytes to create physiologically relevant models that mimic human cardiac tissue. By offering early-stage safety screening, NewCardio helps identify risks such as QT prolongation, arrhythmic potential and ion channel liabilities before candidates advance into costly in vivo studies or clinical trials.

At the core of NewCardio’s offering is a high-throughput optical electrophysiology platform that measures key electrophysiological parameters—action potential duration, calcium transient dynamics and voltage‐gated ion channel activity—under controlled assay conditions. Clients can choose from standardized assay panels or customized protocols that address their specific safety and mechanistic questions. This service model supports integrated workflows for hit‐to‐lead optimization and IND-enabling toxicology screening.

NewCardio serves pharmaceutical, biotechnology and academic research organizations worldwide. By collaborating with medicinal chemists, pharmacologists and regulatory experts, the company aims to streamline preclinical safety evaluation and reduce the time and cost associated with late-stage cardiotoxicity findings. Its offerings are designed to align with international regulatory guidance on proarrhythmia risk assessment, enabling sponsors to generate robust data packages for global submission.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 7/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:NWCI
• CIK: N/A
• Web: www.newcardio.com
• Phone: (877) 332-4324
• Fax: 408-516-5005
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A